Both theorist and domain expert acknowledged that existing epigenetic modulators cause significant off-target effects when used systemically. The debate did not resolve how to achieve brain-specific targeting or identify which specific isoforms are critical in microglia. Source: Debate session sess_SDA-2026-04-04-gap-20260404-microglial-priming-early-ad (Analysis: SDA-2026-04-04-gap-20260404-microglial-priming-early-ad)
Landscape Summary: How can CNS-selective HDAC/DNMT inhibitors be developed to avoid systemic toxicity? is a 0.78 priority gap in pharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
How can CNS-selective HDAC/DNMT inhibitors be developed to avoid systemic toxicity? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: